Vontobel Holding Ltd. Has $430,000 Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vontobel Holding Ltd. increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 27.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,446 shares of the company’s stock after buying an additional 12,511 shares during the period. Vontobel Holding Ltd.’s holdings in Vir Biotechnology were worth $430,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of VIR. Vanguard Group Inc. lifted its stake in Vir Biotechnology by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock valued at $125,362,000 after purchasing an additional 78,216 shares during the last quarter. Millennium Management LLC raised its position in Vir Biotechnology by 94.6% during the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after purchasing an additional 606,804 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Vir Biotechnology by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock valued at $7,238,000 after buying an additional 6,359 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Vir Biotechnology by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after acquiring an additional 58,360 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in Vir Biotechnology by 8.2% during the first quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock valued at $4,640,000 after buying an additional 34,640 shares during the period. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $7.61 on Wednesday. Vir Biotechnology, Inc. has a 1 year low of $7.12 and a 1 year high of $13.09. The stock has a market cap of $1.04 billion, a PE ratio of -1.90 and a beta of 0.46. The firm has a fifty day moving average price of $7.91 and a 200 day moving average price of $8.95.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter in the prior year, the firm earned ($1.45) EPS. Vir Biotechnology’s revenue for the quarter was down 19.0% on a year-over-year basis. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.26 EPS for the current year.

Analyst Ratings Changes

VIR has been the topic of a number of research reports. Barclays boosted their target price on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.80.

Insider Activity at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares of the company’s stock, valued at $90,604.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).